Back to User profile » Dr Zhen Zeng
Papers published by Dr Zhen Zeng:
Transarterial Chemoembolization Combined with Regorafenib and PD-1 Inhibitor as Second-Line Therapy for Unresectable Hepatocellular Carcinoma
Wang D, Zhang W, Gao X, Kong H, Zhang H, Huang J, Zhang M, Chang X, Zeng Z
Cancer Management and Research 2026, 18:578610
Published Date: 29 April 2026
Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
Chang X, Yu S, Pang J, Zhang W, Kong H, Huang J, Zhang G, Zhang H, Gu Y, Chen Y, Yang B, Liu J, Zeng Z
Journal of Hepatocellular Carcinoma 2023, 10:847-861
Published Date: 6 June 2023
Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study
Chen B, Lei J, Zhao H, Dong J, Zeng Z, Li Y, Yu L, Zhou L, Jia A, Lu Y, Cheng J
Journal of Hepatocellular Carcinoma 2022, 9:1171-1185
Published Date: 8 November 2022
Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases
Wu T, Zhang L, Zeng Z, Yan T, Cheng J, Miao X, Lu Y
OncoTargets and Therapy 2021, 14:5447-5453
Published Date: 18 December 2021
Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels
Cheng J, Li Y, Wang X, Dong Z, Chen Y, Zhang R, Huang J, Jin X, Yao J, Ge A, Song L, Lu Y, Zeng Z
Journal of Hepatocellular Carcinoma 2021, 8:1281-1295
Published Date: 27 October 2021
LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells
Chen Y, Zeng Q, Liu X, Fu J, Zeng Z, Zhao Z, Liu Z, Bai W, Dong Z, Liu H, Lu X, Zhu Y, Lu Y
Cancer Management and Research 2018, 10:4421-4438
Published Date: 10 October 2018